Specific resistance upon lentiviral TRAIL transfer by intracellular retention of TRAIL receptors

[1]  T. Griffith,et al.  Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L. , 2005, Blood.

[2]  P. Krammer,et al.  c-FLIPR, a New Regulator of Death Receptor-induced Apoptosis* , 2005, Journal of Biological Chemistry.

[3]  Stephen P. Schoenberger,et al.  CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death , 2005, Nature.

[4]  B. Fang,et al.  Mechanisms of resistance to TRAIL-induced apoptosis in cancer , 2005, Cancer Gene Therapy.

[5]  D. Kabelitz,et al.  Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. , 2004, Immunity.

[6]  W. El-Deiry,et al.  Deficient Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Death Receptor Transport to the Cell Surface in Human Colon Cancer Cells Selected for Resistance to TRAIL-induced Apoptosis* , 2004, Journal of Biological Chemistry.

[7]  K. Nash,et al.  Green fluorescent protein: green cells do not always indicate gene expression , 2004, Gene Therapy.

[8]  T. Kudo,et al.  Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and Aβ-induced cell death , 2004, The Journal of cell biology.

[9]  I. Herr,et al.  AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression , 2004, Gene Therapy.

[10]  F. Zipp,et al.  Regulation of soluble and surface-bound TRAIL in human T cells, B cells, and monocytes. , 2003, Cytokine.

[11]  I. Herr,et al.  Induction of apoptosis in experimental human B cell lymphomas by conditional TRAIL-expressing T cells , 2003, British Journal of Cancer.

[12]  M. Xiong,et al.  Combination of TRAIL gene therapy and chemotherapy enhances antitumor and antimetastasis effects in chemosensitive and chemoresistant breast cancers. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  E. Bröcker,et al.  TRAIL-induced apoptosis and gene induction in HaCaT keratinocytes: differential contribution of TRAIL receptors 1 and 2. , 2003, The Journal of investigative dermatology.

[14]  I. Jeremias,et al.  TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κB , 2003, Oncogene.

[15]  M. von Knebel Doeberitz,et al.  Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. , 2003, Cancer research.

[16]  A. Ashkenazi,et al.  Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. , 2003, Cytokine & growth factor reviews.

[17]  E. De Clercq,et al.  Impact of the Central Polypurine Tract on the Kinetics of Human Immunodeficiency Virus Type 1 Vector Transduction , 2003, Journal of Virology.

[18]  G. Barber,et al.  Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kappa B. , 2003, Blood.

[19]  E. Bröcker,et al.  Proteasome Inhibition Results in TRAIL Sensitization of Primary Keratinocytes by Removing the Resistance-Mediating Block of Effector Caspase Maturation , 2003, Molecular and Cellular Biology.

[20]  M. Xiong,et al.  Long-term tumor-free survival from treatment with the GFP–TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells , 2002, Oncogene.

[21]  A. Grosse-Wilde,et al.  Caspase‐10 is recruited to and activated at the native TRAIL and CD95 death‐inducing signalling complexes in a FADD‐dependent manner but can not functionally substitute caspase‐8 , 2002, The EMBO journal.

[22]  J. Gu,et al.  Mechanisms involved in development of resistance to adenovirus-mediated proapoptotic gene therapy in DLD1 human colon cancer cell line , 2002, Gene Therapy.

[23]  Steven A Curley,et al.  Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. , 2002, Cancer research.

[24]  S. Fulda,et al.  Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression , 2002, Oncogene.

[25]  I. Bechmann,et al.  Lack of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand But Presence of Its Receptors in the Human Brain , 2002, The Journal of Neuroscience.

[26]  Alicia Algeciras-Schimnich,et al.  Molecular Ordering of the Initial Signaling Events of CD95 , 2002, Molecular and Cellular Biology.

[27]  M. Martínez-Lorenzo,et al.  Differential Secretion of Fas Ligand- or APO2 Ligand/TNF-Related Apoptosis-Inducing Ligand-Carrying Microvesicles During Activation-Induced Death of Human T Cells1 , 2001, The Journal of Immunology.

[28]  T. Griffith,et al.  Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[29]  S. Curley,et al.  Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. , 2001, Cancer research.

[30]  R. Ho,et al.  Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. , 2001, Cancer research.

[31]  D. Trono,et al.  High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors. , 2000, Blood.

[32]  J. Norris,et al.  Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  B. Davidson,et al.  Adenoviral-Mediated Transfer of the TNF-Related Apoptosis-Inducing Ligand/Apo-2 Ligand Gene Induces Tumor Cell Apoptosis1 , 2000, The Journal of Immunology.

[34]  J. Blenis,et al.  FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. , 2000, Immunity.

[35]  S. Strom,et al.  Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand , 2000, Nature Medicine.

[36]  S. Ju,et al.  Retroviral membrane display of apoptotic effector molecules. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[37]  W. Anderson,et al.  Subcellular Redistribution of Pit-2 PiTransporter/Amphotropic Leukemia Virus (A-MuLV) Receptor in A-MuLV-Infected NIH 3T3 Fibroblasts: Involvement in Superinfection Interference , 2000, Journal of Virology.

[38]  B. Gliniak,et al.  Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. , 1999, Cancer research.

[39]  J. Dichgans,et al.  Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. , 1999, Biochemical and biophysical research communications.

[40]  R. Offringa,et al.  Immune Escape of Tumors in Vivo by Expression of Cellular Flice-Inhibitory Protein , 1999, The Journal of experimental medicine.

[41]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[42]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[43]  D. Trono,et al.  Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery , 1998, Journal of Virology.

[44]  J. Blenis,et al.  Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade , 1998, Current Biology.

[45]  P. Krammer,et al.  Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage , 1998, European journal of immunology.

[46]  P. Scheurich,et al.  Dominant-negative FADD inhibits TNFR60-, Fas/Apo1- and TRAIL-R/Apo2-mediated cell death but not gene induction , 1998, Current Biology.

[47]  M. Peter,et al.  FLICE Is Predominantly Expressed as Two Functionally Active Isoforms, Caspase-8/a and Caspase-8/b* , 1997, The Journal of Biological Chemistry.

[48]  F. Gage,et al.  Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[49]  J. Yewdell,et al.  Fluorescent conjugates of brefeldin A selectively stain the endoplasmic reticulum and Golgi complex of living cells. , 1995, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[50]  P. Krammer,et al.  Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) , 1995, Nature.

[51]  B. Chesebro,et al.  Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism , 1992, Journal of virology.

[52]  I Nicoletti,et al.  A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. , 1991, Journal of immunological methods.

[53]  M. Volm,et al.  Maintenance of morphology and tumour marker production in human epidermoid lung carcinoma xenografts. , 1987, In vivo.

[54]  J. Miller,et al.  Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system , 1987, Molecular and cellular biology.

[55]  M. Wiznerowicz,et al.  Harnessing HIV for therapy, basic research and biotechnology. , 2005, Trends in biotechnology.

[56]  A. Ashkenazi,et al.  Apo2L/TRAIL and its death and decoy receptors , 2003, Cell Death and Differentiation.

[57]  Michael Weller,et al.  Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo , 2002, Nature Medicine.

[58]  D. Trono.  Lentiviral vectors: turning a deadly foe into a therapeutic agent , 2000, Gene Therapy.